Large Cell Lymphoma Market: By Cell Type (T-Cell and B-Cell); By Treatment Type (Radiation therapy, Mild Chemotherapies, Topical Treatments, and Biological Therapies); By Method of Diagonization and By Geography-Forecast to 2021

  • ID: 3919984
  • Report
  • 152 pages
  • IndustryARC
1 of 3
Lymphoma is a group of blood cancer in which the blood cells, particularly, lymphocytes grow and divide very rapidly than normal rate. Lymphoma is a chronic and life-threatening disease which is supported by enhanced duration of life of blood cells than that of a normal person. Mostly, lymphoma is present in the lymph nodes in the form of solid tumor. Large cell lymphoma is one of the types of lymphoma in which the size of the white blood cells (lymphocytes) is increased in uncontrollable manner which is cancerous in nature. An average size of WBC in large cell lymphoma is around 17-20 micrometers.
Globally, rising prevalence of cancer & lymphomas and increase in medical expenditure due to increasing focus on health and well-being are the prime growth drivers of large cell lymphoma. However, the cost of research and development activities for large cell lymphoma therapies is the key restraint for the growth of large cell lymphoma market.
This report identifies the global large cell lymphoma market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to large cell lymphoma market.

Geographically, Asia Pacific dominated the Global Large Cell Lymphoma Market, and is projected to have fastest growth followed by North America, Europe and Rest of the World (RoW)

This report segments Global Large Cell Lymphoma market on the basis of Cell Type, By Treatment Type, By Method of Diagonization and By Geography as follows:
Large Cell Lymphoma Market, by Cell Type: B - Cell and T-Cell
Large Cell Lymphoma Market, by Treatment Type: Radiation Therapy, Mild Chemotherapies, Topical Treatments and Biological Therapies
The report has focused study on Large Cell Lymphoma Market by Method of Diagonization such as: Laboratory Tests, Biopsy & Lumbar Puncture and Imaging Studies
This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region.

This report identifies all the major companies operating in the Large Cell Lymphoma market. Some of the major companies’ profiles in detail are as follows:
Novartis International AG
AstraZeneca plc
GSK plc
Bayer AG
Sanofi SA
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Large Cell Lymphoma - Market Overview
2. Executive Summary
3. Large Cell Lymphoma Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Large Cell Lymphoma - Market Forces
4.1. Drivers
4.1.1. Rising prevalence of cancer and lymphomas
4.1.2. Increase in medical expenditure due to increasing focus on health and well-being
4.2. Restraints
4.2.1. High cost of R&D and treatment
4.3. Opportunities
4.3.1. Growing awareness about the disease, its consequences and available treatments
4.4. Challenges
4.4.1. Threat of failure during clinical trials
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Large Cell Lymphoma Market, By Cell Type
5.1. T-Cell
5.2. B-Cell
6. Large Cell Lymphoma Market, By Treatment Type
6.1. Radiation Therapy
6.2. Mild Chemotherapies
6.3. Topical Treatments and
6.4. Biological Therapies
7. Large Cell Lymphoma Market, By Method of Diagonization
7.1. Laboratory Tests
7.2. Biopsy & Lumbar Puncture and
7.3. Imaging Studies
8. Global Large Cell Lymphoma Market, By Geography (2014-2021)
8.1. Europe
8.1.1. Germany
8.1.2. France
8.1.3. Italy
8.1.4. Spain
8.1.5. Russia
8.1.6. U.K.
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.3.1. U.S.
8.3.2. Canada
8.3.3. Mexico
8.4. Rest of the World (RoW)
8.4.1. Brazil
8.4.2. Rest of RoW
9. Large Cell Lymphoma - Market Entropy
9.1. Expansion
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply - Contract
10. Company Profiles
10.1. Novartis International AG
10.1.1. Introduction
10.1.2. Financials
10.1.3. Key Insights
10.1.4. Key Strategy
10.1.5. Product Portfolio
10.1.6. SWOT Analysis
10.2. Merck & Co., Inc.
10.2.1. Introduction
10.2.2. Financials
10.2.3. Key Insights
10.2.4. Key Strategy
10.2.5. Product Portfolio
10.2.6. SWOT Analysis
10.3. Gilead Sciences, Inc.
10.3.1. Introduction
10.3.2. Financials
10.3.3. Key Insights
10.3.4. Key Strategy
10.3.5. Product Portfolio
10.3.6. SWOT Analysis
10.4. AstraZeneca plc
10.4.1. Introduction
10.4.2. Financials
10.4.3. Key Insights
10.4.4. Key Strategy
10.4.5. Product Portfolio
10.4.6. SWOT Analysis
10.5. GSK plc
10.5.1. Introduction
10.5.2. Financials
10.5.3. Key Insights
10.5.4. Key Strategy
10.5.5. Product Portfolio
10.5.6. SWOT Analysis
10.6. Sanofi SA
10.6.1. Introduction
10.6.2. Financials
10.6.3. Key Insights
10.6.4. Key Strategy
10.6.5. Product Portfolio
10.6.6. SWOT Analysis
10.7. Pfizer, Inc.
10.7.1. Introduction
10.7.2. Financials
10.7.3. Key Insights
10.7.4. Key Strategy
10.7.5. Product Portfolio
10.7.6. SWOT Analysis
10.8. AbbVie, Inc.
10.8.1. Introduction
10.8.2. Financials
10.8.3. Key Insights
10.8.4. Key Strategy
10.8.5. Product Portfolio
10.8.6. SWOT Analysis
10.9. Bayer AG
10.9.1. Introduction
10.9.2. Financials
10.9.3. Key Insights
10.9.4. Key Strategy
10.9.5. Product Portfolio
10.9.6. SWOT Analysis
10.10. Roche Group
10.10.1. Introduction
10.10.2. Financials
10.10.3. Key Insights
10.10.4. Key Strategy
10.10.5. Product Portfolio
10.10.6. SWOT Analysis

"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Expert Insights
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown